TetraPhase Pharmaceuticals to Present Data at ICAAC Supporting its Lead Antibiotic Candidate Eravacycline’s Effectiveness Against Multi-drug Resistant (MDR) Pathogens

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it will present at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) the results of important research that supports the potential of the company’s next-generation antibiotics portfolio, including its lead candidate eravacycline in the treatment of difficult-to-treat bacterial infections (e.g., serious Gram-negative and biothreat infections).

Help employers find you! Check out all the jobs and post your resume.